PEDIATRICS Vol. 72 No. 2 August 1983, pp. 225-233
This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chan, J. C. M.
Right arrow Articles by Mamunes, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chan, J. C. M.
Right arrow Articles by Mamunes, P.

Hypercalcemia in Children with Disorders of Calcium and Phosphate Metabolism During Long-Term Treatment with 1,25-Dihydroxyvitamin-D3

James C. M. Chan MD1, Reuben B. Young MD1, Uri Alon MD1, and Peter Mamunes MD1

1 Nephrology Section and Genetics-Endocrine-Metabolism Section, Children's Medical Center, and Department of Pediatrics, Medical College of Virginia, Richmond

Forty-two children received 1,25-dihydroxy-vitamin-D3 for treatment of disorders in calcium and phosphate metabolism secondary to chronic renal insufficiency (n = 29), sex-linked dominant hypophosphatemic rickets (n = 9), hypoparathyroidism (n = 2), and pseudohypoparathyroidism (n = 2). Serum calcium, phosphate, and creatinine concentrations were measured monthly for a mean of 26 months and a total of 1,079.5 patient-months. Patients with renal osteodystrophy manifested hypercalcemia (>11 mg/dL) once in every 13 months of treatment on the average. Of three children with hypophosphatemic rickets who experienced hypercalcemia, two proved to have tertiary hyperparathyroidism. Among children with hypoparathyroidism and pseudohypoparathyroidism, three episodes of hypercalcemia were observed during 124.5 patient-months, an incidence of one hypercalcemic episode per 39 treatment months. Renal function, as represented by reciprocals of serum creatinine determined retrospectively for a mean of 22 months before and prospectively for a mean of 26 months after initiation of 1,25-dihydroxyvitamin-D3 treatment, underwent no significant changes except in seven of 29 children with chronic renal insufficiency, six of whose rate of renal function deterioration increased on the treatment and one whose rate decreased. With one exception, hypercalcemia was associated in all cases with accelerated renal function deterioration. Before and after initiation of treatment with 1,25-dihydroxyvitamin-D3 the mean calcium x phosphate solubility products were 42.9 and 47.2, respectively. Values less than 60 are accepted as normal. Hypercalcemia is an occasional concomitant of such treatment and a more rapid deterioration of renal function may occur in some of the patients treated with 1,25-dihydroxyvitamin-D3. Thus, careful monitoring of concentrations of serum calcium, phosphate, and creatinine must accompany 1,25-dihydroxy-vitamin-D3 therapy.

Submitted on August 2, 1982
Accepted on November 22, 1982




This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
K. K. Winer, N. Sinaii, D. Peterson, B. Sainz Jr., and G. B. Cutler Jr.
Effects of Once Versus Twice-Daily Parathyroid Hormone 1-34 Therapy in Children with Hypoparathyroidism
J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3389 - 3395.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
K. K. Winer, C. W. Ko, J. C. Reynolds, K. Dowdy, M. Keil, D. Peterson, L. H. Gerber, C. McGarvey, and G. B. Cutler Jr.
Long-Term Treatment of Hypoparathyroidism: A Randomized Controlled Study Comparing Parathyroid Hormone-(1-34) Versus Calcitriol and Calcium
J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4214 - 4220.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
K. K. Winer, J. A. Yanovski, B. Sarani, and G. B. Cutler Jr.
A Randomized, Cross-Over Trial of Once-Daily Versus Twice-Daily Parathyroid Hormone 1-34 in Treatment of Hypoparathyroidism
J. Clin. Endocrinol. Metab., October 1, 1998; 83(10): 3480 - 3486.
[Abstract] [Full Text]